Opioids

Washington, D.C. – Rep. Jamie Raskin, Ranking Member of the Committee on Oversight and Accountability, U.S.

Washington, D.C. (July 28, 2023)—Rep. Jamie Raskin, Ranking Member of the Committee on Oversight and Accountability, led Democrats in urging bipartisan support for the reauthorization of the Office of National Drug Control Policy (ONDCP), an agency critical in the Biden-Harris Administration's efforts to fight the drug addiction epidemic and curb overdose deaths.

Washington, D.C. (July 27, 2023)—Below is Ranking Member Jamie Raskin's opening statement, as prepared for delivery, at today's Committee on Oversight and Accountability hearing with Dr. Rahul Gupta, Director of the Office of National Drug Control Policy.

Washington, D.C. (June 28, 2022)—Yesterday, Rep. Carolyn B. Maloney, Chairwoman of the Committee on Oversight and Reform, held a hearing with Dr.

Washington D.C. (June 24, 2022)— On Monday, June 27, 2022, at 1:30 p.m. E.T., Rep. Carolyn B.

Washington D.C. (April 22, 2022)— On Wednesday, April 27, 2022, at 10:00 a.m. ET, Rep. Carolyn B.

Washington, D.C. (April 13, 2022)—Today, Rep. Carolyn B. Maloney, the Chairwoman of the Committee on Oversight and Reform, released an interim staff report entitled, The Firm and the FDA: McKinsey & Company's Conflicts of Interest at the Heart of the Opioid Epidemic. The report presents preliminary findings from the Committee's investigation into McKinsey's consulting work during the opioid epidemic.